GLP-1 receptor agonists and uses thereof

1. A method of treating a disease or disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I

or a pharmaceutically acceptable salt thereof, wherein

each R 1 is independently halogen, —CN, —C 1-3 alkyl, or —OC 1-3 alkyl, wherein the alkyl of C 1-3 alkyl and OC 1-3 alkyl is substituted with 0 to 3 F atoms;

m is 0, 1, 2, or 3;

each R 2 is independently F, Cl, or —CN;

p is 0, 1 or 2;

each R 3 is independently F, —OH, —CN, —C 1-3 alkyl, —OC 1-3 alkyl, or —C 3-4 cycloalkyl, or 2 R 3 s may together cyclize to form —C 3-4 spirocycloalkyl, wherein the alkyl of C 1-3 alkyl and OC 1-3 alkyl, cycloalkyl, or spirocycloalkyl may be substituted as valency allows with 0 to 3 F atoms and with 0 to 1 —OH;

q is 0, 1, or 2;

Y is CH or N;

R 4 is —C 1-3 alkyl, —C 0-3 alkylene-C 3-6 cycloalkyl, —C 0-3 alkylene-R 5 , or —C 1-3 alkylene-R 6 , wherein said alkyl may be substituted as valency allows with 0 to 3 substituents independently selected from 0 to 3 F atoms and 0 to 1 substituent selected from —C 0-1 alkylene-CN, —C 0-1 alkylene-OR O , and —N(R N ) 2 , and

wherein said alkylene and cycloalkyl may be independently substituted as valency allows with 0 to 2 substituents independently selected from 0 to 2 F atoms and 0 to 1 substituent selected from —C 0-1 alkylene-CN, —C 0-1 alkylene-OR O , and —N(R N ) 2 ;

R 5 is a 4- to 6-membered heterocycloalkyl, wherein said heterocycloalkyl may be substituted with 0 to 2 substituents as valency allows independently selected from:

0 to 1 oxo (═O),

0 to 1 —CN,

0 to 2 F atoms, and

0 to 2 substituents independently selected from —C 1-3 alkyl and —OC 1-3 alkyl, wherein the alkyl of C 1-3 alkyl and OC 1-3 alkyl may be substituted with 0 to 3 substituents as valency allows independently selected from:

0 to 3 F atoms,

0 to 1 —CN, and

0 to 1 —OR O ;

R 6 is a 5- to 6-membered heteroaryl, wherein said heteroaryl may be substituted with 0 to 2 substituents as valency allows independently selected from:

0 to 2 halogens,

0 to 1 substituent selected from —OR O and —N(R N ) 2 , and

0 to 2 —C 1-3 alkyl, wherein the alkyl may be substituted with 0 to 3 substituents as valency allows independently selected from:

0 to 3 F atoms, and

0 to 1 —OR O ;

each R O is independently H, or —C 1-3 alkyl, wherein C 1-3 alkyl may be substituted with 0 to 3 F atoms;

each R N is independently H, or —C 1-3 alkyl;

Z 1 is CH or N;

Z 2 and Z 3 are each independently —CR Z or N, provided that when Z 1 or Z 3 is N, Z 2 is —CR Z ; and

each R Z is independently H, F, Cl, or —CH 3 ; and

wherein the disease or disorder is selected from the group consisting of T1D, T2DM, pre-diabetes, idiopathic T1D, LADA, EOD, YOAD, MODY, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, kidney disease, diabetic retinopathy, adipocyte dysfunction, visceral adipose deposition, sleep apnea, obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, cardiovascular disease, atherosclerosis, coronary artery disease, peripheral vascular disease, hypertension, endothelial dysfunction, impaired vascular compliance, congestive heart failure, myocardial infarction, stroke, hemorrhagic stroke, ischemic stroke, traumatic brain injury, pulmonary hypertension, restenosis after angioplasty, intermittent claudication, post-prandial lipemia, metabolic acidosis, ketosis, arthritis, osteoporosis, Parkinson's Disease, left ventricular hypertrophy, peripheral arterial disease, macular degeneration, cataract, glomerulosclerosis, chronic renal failure, metabolic syndrome, syndrome X, premenstrual syndrome, angina pectoris, thrombosis, atherosclerosis, transient ischemic attacks, vascular restenosis, impaired glucose metabolism, conditions of impaired fasting plasma glucose, hyperuricemia, gout, erectile dysfunction, skin and connective tissue disorders, psoriasis, foot ulcerations, ulcerative colitis, hyper apo B lipoproteinemia, Alzheimer's Disease, schizophrenia, impaired cognition, inflammatory bowel disease, short bowel syndrome, Crohn's disease, colitis, irritable bowel syndrome, Polycystic Ovary Syndrome, and addiction.

2. The method of claim 1 , wherein the compound is a compound of Formula II

or a pharmaceutically acceptable salt thereof, wherein

m is 0 or 1;

R 2 is F;

p is 0, or 1; and

q is 0 or 1.

3. The method of claim 1 , wherein the compound is a compound of Formula III

or a pharmaceutically acceptable salt thereof, wherein

m is 0 or 1;

R 2 is F;

p is 0, or 1;

R 3 is —C 1-2 alkyl, wherein C 1-2 alkyl may be substituted as valency allows with 0 to 3 F atoms; and

q is 0 or 1.

4. The method of claim 1 , wherein each R 1 is independently F, Cl, —CN, —CH 3 , or —CF 3 .

5. The method of claim 1 , wherein

R 4 is —CH 2 —R 5 , wherein R 5 is the 4- to 5-membered heterocycloalkyl, wherein said heterocycloalkyl may be substituted with 0 to 2 substituents as valency allows independently selected from:

0 to 2 F atoms, and

0 to 1 substituent selected from —OCH 3 and —CH 2 OCH 3 .

6. The method of claim 1 , wherein the heterocycloalkyl of R 5 is a monovalent radical of

wherein the heterocycloalkyl may be substituted with 0 to 2 substituents as valency allows independently selected from:

0 to 1 oxo (O═),

0 to 1 —CN,

0 to 2 F atoms, and

0 to 2 substituents independently selected from —C 1-3 alkyl and —OC 1-3 alkyl, wherein the alkyl of C 1-3 alkyl and OC 1-3 alkyl may be independently substituted with 0 to 3 substituents as valency allows independently selected from:

0 to 3 F atoms,

0 to 1 —CN, and

0 to 1 —OR O .

7. The method of claim 1 , wherein

R 4 is —CH 2 —R 6 , wherein R 6 is the 5-membered heteroaryl, wherein said heteroaryl may be substituted with 0 to 2 substitutents as valency allows independently selected from:

0 to 2 halogens, wherein the halogen is independently selected from F and Cl,

0 to 1 —OCH 3 , and

0 to 1 —CH 3 , —CH 2 CH 3 , —CF 3 , or —CH 2 CH 2 OCH 3 .

8. The method of claim 1 , wherein said heteroaryl of R 6 is a monovalent radical of

and wherein said heteroaryl may be substituted with 0 to 2 substituents as valency allows independently selected from:

0 to 2 halogens,

0 to 1 substituent selected from —OR O and —N(R N ) 2 , and

0 to 2 —C 1-3 alkyl, wherein the alkyl may be substituted with 0 to 3 substituents as valency allows independently selected from:

0 to 3 F atoms, and

0 to 1 —OR O .

9. A method for treating disease or disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound, wherein the compound is

or a pharmaceutically acceptable salt thereof, and wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, adipocyte dysfunction, obesity, eating disorders, weight gain from the user of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis, cirrhosis, hepatocellular carcinoma, and a cardiovascular disease.

10. A method for treating a disease or disorder comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound, wherein the compound is 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof, and wherein the disease or disorder is selected from the group consisting of T2DM, pre-diabetes, malnutrition-related diabetes, gestational diabetes, hyperglycemia, insulin resistance, hepatic insulin resistance, impaired glucose tolerance, diabetic neuropathy, diabetic nephropathy, diabetic retinopathy, adipocyte dysfunction, obesity, eating disorders, weight gain from the use of other agents, excessive sugar craving, dyslipidemia, hyperinsulinemia, NAFLD, NASH, fibrosis, NASH with fibrosis cirrhosis, hepatocellular carcinoma, and a cardiovascular disease.

11. The method of claim 10 , wherein the compound is 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

12. The method of claim 10 , wherein the compound is a pharmaceutically acceptable salt of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid.

13. The method of claim 10 , wherein the compound is 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 2-[(4-{6-[(4-cyano-2-fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6carboxylic acid.

14. The method of claim 1 , wherein the compound is 2-{[4-(6-{[(4-cyano-2-fluorophenyl)methyl-d2)]oxy}pyridin-2-yl)piperidin-1-yl]methyl}-1-[(2S)-oxetan-2-ylmethyl]-1H-benzimidazole-6-carboxylic acid, or a pharmaceutically acceptable salt thereof.

15. The method of claim 1 , wherein the disease or disorder is selected from the group consisting of obesity, eating disorders, weight gain from use of other agents, excessive sugar craving, and dyslipidemia.

16. The method of claim 1 , wherein the disease or disorder is obesity.

17. The method of claim 9 , wherein the disease or disorder is obesity.

18. A method for treating obesity comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound, wherein the compound is 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid, or a pharmaceutically acceptable salt thereof.

19. The method of claim 18 , wherein the compound is 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

20. The method of claim 18 , wherein the compound is a pharmaceutically acceptable salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

21. The method of claim 18 , wherein the compund is 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

22. The method of claim 16 , wherein the disease or disorder is obesity.

23. A method for treating T2DM comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound, wherein the compound is 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid, or a pharmaceutically acceptable salt thereof.

24. The method of claim 23 , wherein the compound is 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

25. A method for treating NASH, or NASH with fibrosis, comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compound, wherein the compound is 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid, or a pharmaceutically acceptable salt thereof.

26. The method of claim 25 , wherein the compound is 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

27. A method for treating NAFLD comprising administering to a mammal in need of such treatment a therapeutically effective amount of a compund, wherein the compound is 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid, or a pharmaceutically acceptable salt thereof.

28. The method of claim 13 , wherein the compound is 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

29. The method of claim 23 , wherein the compound is a pharmaceutically acceptable salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

30. The method of claim 25 , wherein the compound is a pharmaceutically acceptable salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.

31. The method of claim 27 , wherein the compound is a pharmaceutically acceptable salt of 2-[(4-{6-[( 4-cyano-2fluorobenzyl)oxy]pyridin-2-yl}piperidin-1-yl)methyl]-1-[(2S)-oxeyan-2-ylmethyl ]-1H-benzimidazole-6-carbocyclic acid.